RAPH · Raphael Pharmaceutical Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-11-20 | Louria Hayon Igal |
Director, Chief Technology Officer |
Exercise↓
Filing footnotes — Warrants to purchase Common Stock (Direct)
The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table. |
Warrants to purchase Common Stock
|
350,000 |
| 2025-11-20 | Louria Hayon Igal |
Director, Chief Technology Officer |
Exercise↑
|
Common Stock
|
350,000 |
| 2025-03-10 | Eliya Yehuda |
Director |
Award↑
Filing footnotes — Warrant to purchase Common Stock (Direct)
200,000 warrants to purchase Common Stock of the issuer were received as compensation for the reporting person's service as a director of the issuer's board of directors pursuant to a service agreement by and between the issuer and the reporting person, entered on March 10, 2025. The Warrants are exercisable immediately and will expire on March 10, 2026. |
Warrant to purchase Common Stock
|
200,000 |
| 2025-03-05 | Dhadha Ajay Kumar |
Director |
Award↑
Filing footnotes — Warrant to purchase Common Stock (Direct)
350,000 shares of Common Stock and 250,000 Warrants to purchase shares of Common Stock of the issuer were received as compensation for the reporting person's service as a director and chairman of the Issuer's board of directors pursuant to a service agreement by and between the issuer and the reporting person, entered on March 5, 2025. The Warrants are exercisable immediately and will expire on December 31, 2026. |
Warrant to purchase Common Stock
|
250,000 |
| 2025-03-05 | Dhadha Ajay Kumar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
350,000 shares of Common Stock and 250,000 Warrants to purchase shares of Common Stock of the issuer were received as compensation for the reporting person's service as a director and chairman of the Issuer's board of directors pursuant to a service agreement by and between the issuer and the reporting person, entered on March 5, 2025. The Warrants are exercisable immediately and will expire on December 31, 2026. |
Common Stock
|
350,000 |
| 2025-03-02 | Pilo Shlomo |
Director, Chief Executive Officer, 10% Owner |
Award↑
Filing footnotes — Common Stock (Direct)
200,000 shares of Common Stock and 100,000 Warrants to purchase Common Stock of the issuer were acquired by the reporting person for a combined purchase price of $0.50 per share of Common Stock and accompanying Warrant to purchase Common Stock. The Warrants are exercisable immediately and will expire on July 15, 2026. |
Common Stock
|
200,000 |
| 2025-03-02 | Pilo Shlomo |
Director, Chief Executive Officer, 10% Owner |
Award↑
Filing footnotes — Warrant to purchase Common Stock (Direct)
200,000 shares of Common Stock and 100,000 Warrants to purchase Common Stock of the issuer were acquired by the reporting person for a combined purchase price of $0.50 per share of Common Stock and accompanying Warrant to purchase Common Stock. The Warrants are exercisable immediately and will expire on July 15, 2026. |
Warrant to purchase Common Stock
|
100,000 |
| 2023-11-25 | Eliya Yehuda |
Director |
Award↑
|
Common Stock
|
150,000 |
| 2023-08-29 | Louria Hayon Igal |
Director, Chief Technology Officer |
Exercise↓
Filing footnotes — Warrants to purchase Common Stock (Direct)
The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table. |
Warrants to purchase Common Stock
|
999,000 |
| 2023-08-29 | Louria Hayon Igal |
Director, Chief Technology Officer |
Exercise↑
|
Common Stock
|
999,000 |
| 2022-12-05 | Eliya Yehuda |
Director |
Award↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
The warrants are exercisable immediately. |
Warrants to Purchase Common Stock
|
202,000 |
| 2022-12-05 | Pilo Shlomo |
Director, Chief Executive Officer, 10% Owner |
Award↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
The warrants are exercisable immediately. |
Warrants to Purchase Common Stock
|
1,000,000 |
| 2022-12-05 | Ofir Guy |
Director, Chief Financial Officer |
Award↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
The warrants are exercisable immediately. |
Warrants to Purchase Common Stock
|
1,000,000 |
| 2022-12-05 | Press Joseph |
Director |
Award↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
The warrants are exercisable immediately. |
Warrants to Purchase Common Stock
|
105,000 |
| 2022-12-05 | Louria Hayon Igal |
Director, Chief Technology Officer |
Award↑
Filing footnotes — Warrants to Purchase Common Stock (Direct)
The warrants are exercisable immediately. |
Warrants to Purchase Common Stock
|
999,000 |
| 2022-07-26 | Press Joseph |
Director |
Award↑
|
Common Stock
|
280,000 |
| 2022-07-26 | Ofir Guy |
Director, Chief Financial Officer |
Award↑
|
Common Stock
|
1,000,000 |
| 2022-05-12 | Eliya Yehuda |
Director |
Expiration↓
Filing footnotes — Warrant to purchase Common Stock (Direct)
202,000 warrants to purchase Common Stock of the issuer expired on May 12, 2024, and are no longer beneficially owned by the reporting person. |
Warrant to purchase Common Stock
|
202,000 |